The WACC of Vietnam Pharmaceutical Corp (DVN.VN) is 9.3%.
| Range | Selected | |
| Cost of equity | 8.10% - 12.50% | 10.30% |
| Tax rate | 7.80% - 8.60% | 8.20% |
| Cost of debt | 4.50% - 5.70% | 5.10% |
| WACC | 7.4% - 11.3% | 9.3% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 0.56 | 0.84 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 8.10% | 12.50% |
| Tax rate | 7.80% | 8.60% |
| Debt/Equity ratio | 0.21 | 0.21 |
| Cost of debt | 4.50% | 5.70% |
| After-tax WACC | 7.4% | 11.3% |
| Selected WACC | 9.3% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for DVN.VN:
cost_of_equity (10.30%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (0.56) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.